In the end, it was a tie. Sanofi and Novo Nordisk both won FDA approval for their next-gen diabetes combos Monday. Now, it's a mano-a-mano fight for share…

Note to drugmakers negotiating with payers: It’s not the price tag that’s the problem. It's budget impact, and Amgen is working those numbers on its new…

Sanofi and Regeneron's cholesterol-fighter Praluent might have had a chance to take the lead in the PCSK9 sales race, but that fuel injection didn’t come…

An analysis of recently launched meds holds some clues to successful—and not so successful—rollouts.

Cheered by “extraordinarily high” efficacy in chemo-free combo studies, Roche is powering into late-stage trials with two different melanoma-fighting cocktails…

Two prominent doctors have flagged a serious and unexpected side effect linked to the immuno-oncology drugs taking cancer treatment by storm: heart damage that…

Counting on a novel nasal-spray device to set it apart from its rivals, drug delivery specialist OptiNose is preparing to file its new chronic rhinosinusitis…

It’s been a tried-and-true tactic: Combine two aging drugs into one pill and voila! Brand-new, patent-protected product. But the selling power of convenience…

Multiple sclerosis drugmakers are in a fix: These days, the U.S. market isn’t delivering the kind of growth that had been fueling big increases in sales.…

Launches